Perspective Therapeutics, Inc. (CATX) News
Follow Perspective Therapeutics, Inc. (CATX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Shares of Lobo Technologies Ltd (NASDAQ: LOBO ) rose sharply in pre-market trading after the company reported a year-over-year increase in H1 financial results. Lobo EV Technologies posted a H1 loss of 7 cents per share,
LIVE | Sep 21, 2026, 09:01 AM UTC
L
Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:44 PM UTC
L
Perspective Therapeutics updates presentation on 212Pb pipeline
Perspective Therapeutics updated its corporate presentation to highlight progress across three clinical-stage 212Pb radiopharmaceutical programs and a combined $45B+ solid tumor market opportunity.
REGULATION | Sep 08, 2026, 09:23 PM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
L
Perspective Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Perspective Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
EARNINGS | Aug 11, 2026, 07:53 PM UTC
L
CATX - Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
CATX - Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
EARNINGS | Jul 31, 2026, 10:30 AM UTC
L
CATX - Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
CATX - Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
EQUITY | Jul 28, 2026, 10:30 AM UTC